The PRV sale provides substantial near-term cash runway, but investors should monitor quarterly product revenue growth and patient treatment cadence to assess real commercial traction. A sustained increase in ZEVASKYN treatments and payer diversification beyond Medicaid will be key indicators of scalability.
Price Chart
Executive Summary
Abeona Therapeutics reported its first full year of commercial operations following FDA approval of ZEVASKYN, with $5.8 million in revenue and a net income of $71.2 million in 2025, driven primarily by a $152.4 million gain from the sale of a Rare Pediatric Disease Priority Review Voucher. The company treated its first commercial patient in December 2025 and has expanded its Qualified Treatment Center network, signaling early commercial traction for its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).
Key Financial Metrics
Key Facts
- First commercial patient treated with ZEVASKYN in December 2025; one additional patient treated in Q1 2026.
- Total revenue for 2025 was $5.82 million, including $2.42 million in net product revenue from one patient and $3.4 million in license revenue.
- Gain from sale of Priority Review Voucher (PRV) contributed $152.4 million to net income, which totaled $71.2 million for 2025 (vs. $63.7 million net loss in 2024).
- Cash, cash equivalents, and short-term investments totaled $191.4 million as of December 31, 2025.
- R&D spending decreased to $26.8 million in 2025 from $34.4 million in 2024, while SG&A rose to $65.0 million from $29.9 million due to commercialization efforts.
Financial Impact
Net income turned positive at $71.2M due to $152.4M PRV sale, but core operations remain unprofitable with an $89.4M loss from operations. Product revenue is minimal at $2.4M from one patient.
Risk Factors
- Commercial success is unproven; only two patients treated to date despite FDA approval in April 2025.
- Core operations are not yet profitable; the $71.2M net income is largely non-recurring due to the PRV sale.
- Manufacturing challenges were cited, including a failed batch due to sterility assay issues, raising scalability concerns.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257035 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $5.47 $5.57 | ▲ +1.83% | ▲ +1.01% | $5.03 (−8.14%) |
Aug 14, 2026 6w ago | Institutional Cluster | $5.94 $6.06 | ▲ +2.02% | ▲ +3.21% | $5.03 (−15.40%) |
Aug 13, 2026 7w ago | 8-K | $6.35 $5.96 | ▼ −6.07% | ▼ −4.10% | $5.03 (−20.80%) |
Aug 13, 2026 7w ago | Press Release | $6.35 $5.96 | ▼ −6.07% | ▼ −4.10% | $5.03 (−20.80%) |
Jul 9, 2026 12w ago | Insider Cluster | $6.98 $7.02 | ▲ +0.57% | ▲ +1.13% | $5.03 (−28.01%) |
Jun 15, 2026 15w ago | Insider Cluster | $5.65 $5.72 | ▲ +1.24% | ▲ +3.47% | $5.03 (−11.06%) |
Jun 15, 2026 15w ago | Insider Cluster | $5.65 $5.72 | ▼ −1.24% | ▼ −3.47% | $5.03 (+11.06%) |
Jun 12, 2026 16w ago | 8-K | $5.53 $5.77 | ▲ +4.34% | ▲ +3.67% | $5.03 (−9.13%) |
Jun 10, 2026 16w ago | 8-K | $5.53 $5.65 | ▲ +2.17% | ▲ +1.74% | $5.03 (−9.13%) |
Jun 10, 2026 16w ago | Insider Cluster | $5.36 $5.65 | ▼ −5.41% | ▼ −1.98% | $5.03 (+6.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access